Sp40
MICROBIOME INDUCED COMPLEMENT SYNTHESIZED IN THE GUT PROTECTS AGAINST ENTERIC INFECTIONS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The gut microbiome is implicated in a wide range of physiological processes, and holds great, but unrealized, potential for disease treatment and prevention. In this session, rising investigators demonstrate novel biotherapeutic applications of gut microbes, and how the intestinal bacterial community interacts with an arm of the innate immune system. The talks span the topics of bioengineered probiotics, anti-tumor activities of gut microbes, and introduce the complement system in the gut as an effector of antimicrobial defense.
The gut microbiome is implicated in a wide range of physiological processes, and holds great, but unrealized, potential for disease treatment and prevention. In this session, rising investigators demonstrate novel biotherapeutic applications of gut microbes, and how the intestinal bacterial community interacts with an arm of the innate immune system. The talks span the topics of bioengineered probiotics, anti-tumor activities of gut microbes, and introduce the complement system in the gut as an effector of antimicrobial defense.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
